GATT patent extension upheld in Capoten ruling; Glaxo's Zantac is beneficiary.
This article was originally published in The Tan Sheet
Executive Summary
GATT DRUG PATENT EXTENSIONS UPHELD IN FEDERAL APPEALS COURT RULING that supported Bristol-Myers Squibb's patent infringement claim against Royce Labs. The Washington, D.C. federal appeals court decided Nov. 1 that Royce, despite making a "substantial investment" in developing generic captopril, could not market its product before the new patent expiration date granted to Bristol's prescription cardiovascular drug Capoten under the Uruguay Round Agreements Act.